Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients

Nordic Journal of Psychiatry

Volumn 67, Issue 1, 2013, Pages 22-29

  San, Luis ^a   Bernardo, Miquel ^b   Gómez, Agustín ^c   Martínez, Pedro ^d   González, Beatriz ^e   Peña, Mario ^d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Medical Affairs   (Spain)

^e Health Economics Department   (Spain)

Author keywords

Antipsychotic agents; Patient compliance; Schizophrenia; Treatment outcome

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; DISEASE DURATION; EDUCATIONAL STATUS; FAMILY ATTITUDE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOCIAL STATUS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; EDUCATIONAL STATUS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84873028027     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2012.667150     Document Type: Article

References (34)

1. Bromet EJ, Fenning S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999;46: 871-81.
2. McGrath J, Saha S, Welham J, EL Saadi O, Maccauley C, Chant D. A systematic review of the incidence of schizophrenia: The distribution rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2004;2:13, doi: 10.1186/1741-7015-2-13.
3. Schultz SH, North SW, Shields CG. Schizophrenia: A review. Am Fam Physician 2007;75: 1821-9.
4. Perlick D, Stastny P, Mattis S, Teresi J. Contribution of family, cognitive and clinical dimensions to long-term outcome in schizophrenia. Schizophr Res 1992;6: 257-65.
5. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: A review. Schizophr Bull 2006;32 Suppl 1: S44-63.
6. Müller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004;37 Suppl 2: S141-7.
7. Taylor M, Chaudhry I, Cross M, Mcdonald E, Miller P, Pilowsky L, Strickland P. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 2005;20: 175-81.
8. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24: 287-96.
9. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32, doi: 10.1186/1471-244X-8-32.
10. Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-23.
11. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: From theory to practice. J Clin Psychiatry 2007;68 Suppl 14: 14-9.
12. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry 2011, doi:10.1016/j.comppsych.2010.12.003.
13. Meier J, Becker T, Patel A, Robson D, Schene A, Kikkert M, et al. Effect of medication-related factors on adherence in people with schizophrenia: A European multi-centre study. Epidemiol Psychiatr Soc 2010;19: 251-9.
14. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011, doi: 10.1016/j.schres.2010.11.020.
15. Uçok A, Polat A, Cakir S, Genç A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006;256: 37-43.
16. Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, et al. One year outcome in first episode psychosis: Influence of DUP and other predictors. Schizophr Res 2002;54: 231-42.
17. Lenior ME, Dingemans PM, Schene AH, Linszen DH. Predictors of the early 5-year course of schizophrenia: A path analysis. Schizophr Bull 2005;31: 781-91.
18. Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia: A meta-analysis. Schizophr Bull 2001;27: 73-92.
19. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176: 109-13.
20. Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
21. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76-338). Rockville, MD: National Institute of Mental Health. P. 218 - 22.
22. Chabungbam G, Avasthi A, Sharan P. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 2007;61: 587-93.
23. Hirsch S, Bowen J, Emami J, Cramer P, Jolley A, Haw C, Dickinson M. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Br J Psychiatry 1996;168: 49-56.
24. Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: The influence of clinical variables, relatives'knowledge and expressed emotion. Psychol Med 2003;33: 91-6.
25. Montero I, Gómez-Beneyto M, Ruiz I, Puche E, Adam A. The influence of family expressed emotion on the course of schizophrenia in a sample of Spanish patients. A two-year follow-up study. Br J Psychiatry 1992;161: 217-22.
26. Marom S, Munitz H, Jones PB, Weizman A, Hermesh H. Expressed emotion: Relevance to rehospitalization in schizophrenia over 7 years. Schizophr Bull 2005;31: 751-8.
27. Ascher-Svanum H, Faries De, Zhu B, Ernst Fr, Swartz Ms, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67: 453-60.
28. Byerly MJ, Nakonezny Pa, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30: 437-52.
29. Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: Impact on treatment adherence. CNS Drugs 2007;21: 129-41.
30. Davies LM, Drummond MF. Economics and schizophrenia: The real cost. Br J Psychiatry 1994;25 Suppl: 18-21.
31. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: A 12- and 24-month follow-up from the e-STAR Database in Spain. Appl Health Econ Health Policy 2008;6: 41-53.
32. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160: 1209-22.
33. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij De Weg H, Eriksson L, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26: 501-9.
34. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. CNS Drugs 2009;23: 649-59.